Markets:

Overview

News

Currencies

International

Treasuries

Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

14.38 -0.32 (-2.18%)

Streaming Delayed Price Updated: 10:54 AM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

34 35 Next >

MindMed Shareholders Vote For All Six Company Nominees At Annual Meeting, Current R&D Path Upheld ↗

June 27, 2023

MindMed’s (NASDAQ: MNMD) heated proxy battle over R&D strategy might finally be coming to an end.

Via Benzinga

FCM Received Significant Support from Shareholders, Disappointed that “Passive” Investors Saw Fit to Give Incumbent Directors Another Chance to Disappoint

June 22, 2023

From Concerned Shareholders of Company MindMed

Via GlobeNewswire

MindMed to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

June 22, 2023

From Mind Medicine (MindMed) Inc.

Via Business Wire

MindMed Announces Election of All Six Company Nominees at Annual Meeting

June 21, 2023

From Mind Medicine

Via Business Wire

MindMed Provides Overview of Clinical Progress and Corporate Updates at Investor Day

June 20, 2023

From Mind Medicine

Via Business Wire

Upward Trend In Major Psychedelic Compound-Based Research & Development Stocks Continue ↗

June 17, 2023

There are 6 constituents in our munKNEE Psychedelic Drug Stocks Index and 5 of them advanced this week and are now all up MTD.

Via Talk Markets

FCM Denounces MindMed’s Manipulation of Corporate Machinery to Protect Incumbent Board of Directors

June 15, 2023

From Concerned Shareholders of Company MindMed

Via GlobeNewswire

MindMed Adjourns Annual General Meeting of Shareholders

June 15, 2023

From Mind Medicine

Via Business Wire

Major Psychedelic Compound-Based Research & Development Stocks: June Update ↗

June 10, 2023

Psychedelic Drug Stocks Index has been revamped with the removal of Cybin (CYBN) which has dropped below $100M in market capitalization leaving 6 constituents in the Index

Via Talk Markets

Creso Pharma's LOI For Import Of Swiss MDMA And Psilocybin Therapeutics To Australia ↗

June 09, 2023

Australia-based cannabis and psychedelics company Creso Pharma Ltd. (OTCMKTS: COPHF) inked a Letter of Intent (LOI) with Swiss pharmacy Apotheke Dr.

Via Benzinga

MindMed Urges Shareholders to Vote TODAY for Company Nominees Ahead of June 13th Deadline

June 09, 2023

From MindMed

Via Business Wire

Leading Proxy Advisory Firm Glass Lewis Recommends MindMed Shareholders Vote FOR All Six Company Nominees

June 08, 2023

From Mind Medicine (MindMed) Inc.

Via Business Wire

FCM Plans for MM-120 (LSD) FDA Approval in 2026 And Extends Share Lockup Until June 15, 2026

June 07, 2023

From Concerned Shareholders of Company MindMed

Via GlobeNewswire

MindMed to Host Investor Day June 2023

June 07, 2023

From Mind Medicine

Via Business Wire

Numinus' Clinical Arm To Lead Enrollment Site For MindMed's Phase 2b LSD Study ↗

June 05, 2023

Mental healthcare company Numinus Wellness (OTCQX: NUMIF) announced its contract research organization Cedar Clinical Research (CCR) is a top research site for MindMed's (NASDAQ: MNMD) Phase 2b stud

Via Benzinga

Leading Proxy Advisory Firm ISS Recommends MindMed Shareholders Vote FOR All Six Company Nominees

June 05, 2023

From MindMed

Via Business Wire

FCM Predicts Psychedelic Revolution In 2024: Urges Shareholders to Position MindMed for Success with a Reconstituted Board

June 02, 2023

From Concerned Shareholders of Company MindMed

Via GlobeNewswire

May Summary Of Largest Psychedelic Compound-Based Drug Stock Performances ↗

June 01, 2023

Only two of the seven largest psychedelic compound-based drug stocks tracked, advanced in May.

Via Talk Markets

MindMed to Participate at Upcoming Investor Conferences

June 01, 2023

From Mind Medicine

Via Business Wire

Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More ↗

May 31, 2023

Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics...

Via Benzinga

FCM Pledges to Lock Up its MindMed Shares Until June 2025 to Demonstrate its Alignment with Fellow Shareholders and Confidence in its Plan to Restore MindMed

May 30, 2023

From Concerned Shareholders of Company MindMed

Via GlobeNewswire

MindMed And FCM Holdings' Dispute Over Clinical Path Forward Deepens ↗

May 30, 2023

The proxy battle over MindMed’s (NASDAQ: MNMD) control has now evolved to each side requesting their position on what is best for the company's future to be validated by independent sources, vis-a-vis...

Via Benzinga

FCM Concerned MindMed’s Mismanagement Threatens Mental Health for Millions

May 25, 2023

From Concerned Shareholders of Company MindMed

Via GlobeNewswire

MindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and Shareholders

May 25, 2023

From Mind Medicine (MindMed) Inc.

Via Business Wire

MindMed Calls FDA Experts To Validate LSD Drug Development Strategy ↗

May 25, 2023

In a new chapter of the management quarrel between MindMed (NASDAQ: MNMD) executives and shareholder group FCM Holdings, t

Via Benzinga

MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy

May 25, 2023

From Mind Medicine (MindMed) Inc.

Via Business Wire

MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting

May 24, 2023

From MindMed

Via Business Wire

Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More ↗

May 23, 2023

Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application...

Via Benzinga

MindMed's LSD Study For Anxiety Treatment Enrolls And Doses 100 Participants, More Expected ↗

May 19, 2023

MindMed’s (NASDAQ: MNMD) Phase 2b clinical trial on proprietary LSD compound MM-120 targeting Generalized Anxiety Disorder (GAD) is over 50% enrolled and dosed.

Via Benzinga

MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)

May 17, 2023

From MindMed

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.